by
GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX)
today announced that it has received notification from the U.S. Drug
Enforcement Agency (DEA) that prior to making any decisions on the
pending applications, the DEA intends to distribute regulations that
govern the program of growing marijuana for scientific research under
DEA registration. GB Sciences is one of just 33 companies that applied
to the DEA to become registered under the Controlled Substances Act
(CSA) to grow (manufacture) marijuana in order to supply DEA-registered
researchers in the United States. Last week, after a three-year delay
and following pressure by Congress, patients and researchers, the DEA
announced that it will move forward with creating revised regulations
and with reviewing the applications.
"We are well-positioned to meet and exceed the DEA's criteria, and we intend to aggressively pursue federal licensure," said Dr. Andrea Small-Howard, Chief Science Officer and Director of GB Sciences.
"The sophistication of our facilities, our team's deep scientific
experience, and our groundbreaking cannabinoid therapies are
unparalleled in the United States."
According to the letter from the DEA, it is looking to facilitate
research, advance scientific understanding about the effects of
marijuana, and potentially aid in the development of safe and effective
drug products that may be approved for marketing by the Food and Drug
Administration.
GB Sciences' 28,000-square-foot facility in Las Vegas, Nevada features one of the only pharmaceutical-grade "cleanroom-type" grows in the United States.
The company's groundbreaking research program, led by Dr. Small-Howard
with nine university research partners in the U.S. and internationally, has
created a patent portfolio of cannabis-based therapies that cover over
60 disease and health conditions including Parkinson's disease,
neuropathic pain, and cardiac hypertrophy.
About GB Sciences
GB Sciences, Inc. (OTCQB: GBLX)
is a diverse cannabis company, focused on standardized cultivation and
production methods; as well as biopharmaceutical research and
development.
The Company's goal is creating safe, standardized,
pharmaceutical-grade, cannabinoid therapies that target a variety of
medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
Forward-Looking Statements
This press release may
contain statements relating to future results or events, which are
forward-looking statements. Words such as "expects", "intends",
"plans", "may", "could", "should", "anticipates", "likely", "believes"
and words of similar import may identify forward-looking statements.
These statements are not historical facts, but instead represent only
the Company's belief regarding future events, many of which, by their
nature, are inherently uncertain and outside of the Company's control.
It is possible that the Company's actual results and financial condition
may differ, possibly materially, from the anticipated results and
financial condition indicated in these forward-looking statements.
Further, information concerning the Company and its business, including
factors that potentially could materially affect the Company's business
and financial and other results, are contained in the Company's filings
with the Securities and Exchange Commission, available at www.sec.gov.
All forward-looking statements included in this press release are made
only as of the date of this press release, and we do not undertake any
obligation to publicly update or correct any forward-looking statements
to reflect events or circumstances that subsequently occur or of which
we hereafter become aware.
Note: Although the Company's research and development activities are
not illegal, the production and sale of cannabis products violate
federal laws as they presently exist.
No comments:
Post a Comment